http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2014336265-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f5b0cb3a13a12fe836a96d161ae73a18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf32b60391b469c41e86c353437f5751 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_544671b5c069e5be15dcec71f980f0d2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cda4382b0099c31b63d4d7c08b35ed64 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C323-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-661 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-145 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C323-32 |
| filingDate | 2014-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71ec4c7c529bd3dd90c22cc9d9662a89 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_362af0f6a73162c4b784cce5efe11cb3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7eed99e4d0ce914088d6d74b879e454 |
| publicationDate | 2014-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2014336265-A1 |
| titleOfInvention | Dosage Regimen of Diaryl Sulfide Derivatives |
| abstract | A compound of formula I: n n n n n n n n n n n n wherein X is O, S, SO or SO 2 ; n R 1 is halogen, trihalomethyl, —OH, C 1-7 alkyl, C 1-4 alkoxy, trifluoromethoxy, phenoxy, cyclohexylmethyloxy, pyridylmethoxy, cinnamyloxy, naphthylmethoxy, phenoxymethyl, —CH 2 —OH, —CH 2 —CH 2 —OH, C 1-4 alkylthio, C 1-4 alkylsulfinyl, C 1-4 alkylsulfonyl, benzylthio, acetyl, nitro or cyano, or phenyl, phenylC 1-4 alkyl or phenyl-C 1-4 alkoxy each phenyl group thereof being optionally substituted by halogen, CF 3 , C 1-4 alkyl or C 1-4 alkoxy; n R 2 is H, halogen, trihalomethyl, C 1-4 alkoxy, phenethyl or benzyloxy; n R 3 H, halogen, CF 3 , OH, C 1-7 alkyl, C 1-4 alkoxy, benzyloxy, phenyl or C 1-4 alkoxymethyl; n each of R 4 and R 5 , independently is H or a residue of formula (a) n n n n n n n n n n n n n n n n wherein each of R 8 and R 9 , independently, is H or C 1-4 alkyl optionally substituted by halogen; n and n is an integer from 1 to 4; n or a pharmaceutically acceptable salt, hydrate, solvate, isomer or prodrug thereof; n or a compound of formula II n n n n n n n n n n n n n n n n wherein n R 1a is halogen, trihalomethyl, C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylthio, C 1-4 alkylsulifinyl, C 1-4 alkyl-sulfonyl, aralkyl, optionally substituted phenoxy or aralkyloxy; n R 2a is H, halogen, trihalomethyl, C 1-4 alkyl, C 1-4 alkoxy, aralkyl or aralkyloxy; n R 3a is H, halogen, CF 3 , C 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkylthio or benzyloxy; n R 4a is H, C 1-4 alkyl, phenyl, optionally substituted benzyl or benzoyl, or lower aliphatic C 1-5 acyl; n R 5a is H, monohalomethyl, C 1-4 alkyl, C 1-4 alkoxy-methyl, C 1-4 alkyl-thiomethyl, hydroxyethyl, hydroxypropyl, phenyl, aralkyl, C 2-4 alkenyl or alkynyl; n R 6a is H or C 1-4 alkyl; n R 7a is H, C 1-4 alkyl or a residue of formula (a) as defined above, n X a is O, S, SO or SO 2 ; and n n a is an integer of 1 to 4; n or a pharmaceutically acceptable salt, hydrate, solvate, isomer or prodrug thereof, n for use in a method of treatment, optionally of an autoimmune condition, n wherein said compound of formula I or II is administered at a dosage lower than the standard daily dosage of said compound during the initial period of treatment and then is increased, optionally stepwise, up to the standard daily dosage of said compound. |
| priorityDate | 2010-05-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 164.